| scholarly article | Q13442814 |
| P50 | author | Sarah Hendrickx | Q94593639 |
| P2093 | author name string | P Cos | |
| J C Dujardin | |||
| L Maes | |||
| P Delputte | |||
| L Lachaud | |||
| G Boulet | |||
| S Rijal | |||
| A Mondelaers | |||
| P2860 | cites work | Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance | Q24633552 |
| Pentavalent antimonials: new perspectives for old drugs | Q28253055 | ||
| Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis | Q28271849 | ||
| Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance | Q28285948 | ||
| Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol | Q28483977 | ||
| Leishmania donovani develops resistance to drug combinations | Q28484463 | ||
| Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? | Q29038941 | ||
| Aminoglycosides: activity and resistance | Q33548221 | ||
| Oral miltefosine for Indian visceral leishmaniasis | Q34529393 | ||
| Injectable paromomycin for Visceral leishmaniasis in India | Q34639916 | ||
| Paromomycin | Q34864208 | ||
| Antimony resistance in leishmania, focusing on experimental research | Q35607561 | ||
| Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. | Q36645795 | ||
| Combination therapy for visceral leishmaniasis | Q37698756 | ||
| Drug resistance in Indian visceral leishmaniasis | Q39222666 | ||
| Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani | Q39226324 | ||
| Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). | Q39444314 | ||
| In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences | Q41844113 | ||
| In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells | Q41901399 | ||
| Leishmania resistance to miltefosine associated with genetic marker | Q42573934 | ||
| Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment | Q44379606 | ||
| Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase B and surface metalloprotease glycoprotein 63 in the Leishmania donovani complex | Q44785806 | ||
| In vitro and in vivo prophylactic and curative activity of the triterpene saponin PX-6518 against cutaneous Leishmania species | Q59275048 | ||
| Kala-azar elimination programme in India | Q64132519 | ||
| Development and characterization of paromomycin-resistant Leishmania donovani promastigotes | Q77352855 | ||
| Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use | Q84100557 | ||
| P433 | issue | 5 | |
| P921 | main subject | miltefosine | Q411787 |
| paromomycin | Q415625 | ||
| Leishmania donovani | Q1950752 | ||
| P304 | page(s) | 1875-1881 | |
| P577 | publication date | 2014-03-11 | |
| P1433 | published in | Parasitology Research | Q15755242 |
| P1476 | title | Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum | |
| P478 | volume | 113 |
| Q39014776 | Artemisinin and its derivatives in treating protozoan infections beyond malaria |
| Q33728704 | Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum |
| Q28550306 | Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain |
| Q39560646 | Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance. |
| Q39014583 | Evaluating drug resistance in visceral leishmaniasis: the challenges |
| Q53120855 | Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum. |
| Q28546940 | Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major |
| Q37023262 | Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovani |
| Q36001763 | Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes |
| Q60303363 | Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure |
| Q90125299 | Impaired development of a miltefosine-resistant Leishmania infantum strain in the sand fly vectors Phlebotomus perniciosus and Lutzomyia longipalpis |
| Q35859984 | In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model |
| Q46481419 | In vitro 'time-to-kill' assay to assess the cidal activity dynamics of current reference drugs against Leishmania donovani and Leishmania infantum |
| Q28540828 | In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis |
| Q50051086 | In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series. |
| Q30380900 | In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization. |
| Q53541333 | Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum. |
| Q39063747 | Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome |
| Q35801671 | Leishmania is not prone to develop resistance to tamoxifen |
| Q40614369 | Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis. |
| Q89842729 | Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection |
| Q91836148 | Transcriptional responses of Leishmania (Leishmania) amazonensis in the presence of trivalent sodium stibogluconate |
| Q58562873 | Visceral leishmaniasis and HIV coinfection: current perspectives |
| Q36887740 | Zinc(II)-Dipicolylamine Coordination Complexes as Targeting and Chemotherapeutic Agents for Leishmania major |
Search more.